ACRS — Aclaris Therapeutics, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1557746 ·
Last close
$5.15
Market Cap
$758.07M
52W High
$6.60
52W Low
$1.74
ADV30
2,345,300
Next earnings
2026-11-05

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 1,629,000 176,000 -23,938,000 -21,505,000 179,693,000 19,167,000 55,112,000
Mar 2026 1,996,000 208,000 -22,192,000 -19,824,000 198,720,000 28,660,000 55,071,000
Dec 2025 1,295,000 -174,000 -21,029,000 -19,795,000 160,460,000 19,960,000 57,378,000
Sep 2025 3,299,000 850,000 -16,333,000 -14,614,000 175,534,000 25,256,000 55,434,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-62,059,000
Investing CF
$3,530,000
Financing CF
$52,294,000
CapEx
$-118,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.58
As of
2026-08-09

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,009,113,000
Inventory
—
Receivables
$4,680,000
ST Investments
$72,389,000
EBIT TTM
$-85,513,000
Pretax Income TTM
$-75,738,000
Interest Exp TTM
—
Analysts
10

Yahoo Snapshot (yfinance, live)

Total Revenue
$8,219,000
EBITDA
$-85,525,000
Free Cash Flow
$-41,970,624
Enterprise Value
$693,392,128
Total Cash
$91,556,000
Total Debt
$1,850,000
Shares Out
147,198,893
Trailing EPS
$-0.58
Book Value
$0.89
ROE
-59.1%
ROA
-29.0%
Div Yield
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 7,826,000 -74,075,000 -64,923,000 160,460,000 57,378,000 103,082,000 -47,113,000
Dec 2024 18,720,000 -52,527,000 -132,065,000 220,327,000 64,773,000 155,554,000 -20,075,000
Dec 2023 31,249,000 -116,314,000 -88,481,000 197,405,000 40,226,000 157,179,000 -78,325,000
Dec 2022 29,752,000 -85,154,000 -86,908,000 254,596,000 56,975,000 197,621,000 -67,567,000

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.79

Max Pain — expiry 2026-12-18

max pain strike: $4.00 · spot: $5.06 · call oi: 2,878 · put oi: 2,343
Expected Move to 2026-12-18: ±$2.23 (44.07%) — implied range $2.83 – $7.29 · ATM straddle on $5.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
DSGN Design Therapeutics, Inc. $758.49M $12.12 —
IVEVF Inventiva S.A. $760.63M $3.22 —
OLMA Olema Pharmaceuticals, Inc. $765.60M $8.75 —
SLNCF Silence Therapeutics plc $745.85M $4.00 —
WVE Wave Life Sciences, Inc. $744.84M $3.78 —

News headlines (Yahoo Finance, 1h cache)

Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP)
2026-08-06 20:35 · Yahoo
Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates
2026-08-06 12:20 · Yahoo
Strength Seen in Aclaris (ACRS): Can Its 5.4% Jump Turn into More Strength?
2026-07-01 12:23 · Yahoo
Aclaris Therapeutics Maps Busy Pipeline Calendar, Plans Phase 2 Asthma Trial for ATI-052
2026-06-04 19:02 · Yahoo
Aclaris Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
2026-05-28 12:30 · Yahoo
Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference
2026-05-08 12:30 · Yahoo
Companies Like Aclaris Therapeutics (NASDAQ:ACRS) Are In A Position To Invest In Growth
2026-05-04 10:04 · Yahoo
Aclaris Therapeutics Announces Positive Full Top Line First-in-Human Results from Phase 1a Healthy Volunteer Clinical Trial of ATI-052, a Novel Potential First-in-Class Anti-TSLP/IL-4Rα Bispecific Ant
2026-04-28 10:30 · Yahoo
Aclaris Therapeutics to Provide Clinical Update on Key Biologic and Oral Inhibitor Programs on April 28, 2026
2026-04-27 20:45 · Yahoo
Aclaris (ACRS) Soars 6.0%: Is Further Upside Left in the Stock?
2026-09-15 12:47 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.